Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD A Randomized Double-blind, Placebo-controlled Trial of Tezepelumab UPSTREAM-COPD

NCT05507242 is registered in ClinicalTrials.gov with Asger Sverrild as lead sponsor.

NCT NCT05507242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD A Randomized Double-blind, Placebo-controlled Trial of Tezepelumab UPSTREAM-COPD
Lead sponsor
Asger Sverrild
Phase
Phase 2
Overall status
Recruiting
Start date
October 25, 2022
Completion date
December 31, 2025
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

airway disease, copd, copd bronchitis, copd exacerbation, immune system disorder